Financial Performance - Revenue for the six months ended June 30, 2021, was RMB 67,404,000, an increase of 14.06% compared to RMB 58,755,000 for the same period in 2020[14]. - Gross profit for the same period was RMB 30,301,000, representing a gross margin of approximately 44.9%, up from RMB 24,549,000 in 2020[14]. - The net profit for the period was RMB 1,231,000, a decrease from RMB 3,054,000 in the same period of 2020, primarily due to increased tax expenses[14]. - The company reported a significant increase in revenue from software development services, which amounted to RMB 48,577,000, compared to RMB 47,561,000 in the previous year[110]. - The company's profit for the six months ended June 30, 2021, was RMB 1,231,000, compared to RMB 3,054,000 for the same period in 2020, representing a decrease of approximately 59.7%[83]. - Total comprehensive income for the period was RMB 695,000, down from RMB 2,064,000 in the previous year, indicating a decline of about 66.4%[84]. Assets and Liabilities - The total assets as of June 30, 2021, amounted to RMB 892,926,000, significantly higher than RMB 258,480,000 as of December 31, 2020[14]. - Total liabilities decreased to RMB 33,381,000 from RMB 59,107,000 in the previous year, indicating improved financial stability[14]. - The company's current assets increased significantly from approximately RMB 172.4 million as of December 31, 2020, to approximately RMB 816.2 million as of June 30, 2021[45]. - Cash and cash equivalents rose from approximately RMB 69.1 million as of December 31, 2020, to approximately RMB 666.7 million as of June 30, 2021[45]. - The company's liabilities as of June 30, 2021, were RMB 1,379,000, slightly up from RMB 1,371,000 as of December 31, 2020[106]. - The company reported a total accounts payable of RMB 3,413,000 as of June 30, 2021, down from RMB 6,265,000 at the end of 2020, indicating a decrease of 45.5%[150]. Equity and Shareholder Information - The total equity increased to RMB 859,545,000 from RMB 199,373,000, reflecting strong growth in shareholder value[14]. - The major shareholder, Mr. Zhai, held 327,600,000 shares, representing approximately 40.95% of the company's issued share capital as of June 30, 2021[56]. - The company's return on equity decreased from 16.6% in 2020 to 0.1% for the six months ended June 30, 2021, primarily due to a significant increase in total equity and a decrease in net profit[51]. Research and Development - The company expanded its R&D team to over 85 personnel by June 2021, enhancing its capabilities in big data and AI[15]. - Research and development expenses surged by 91.4% from RMB 3.5 million for the six months ended June 30, 2020, to RMB 6.7 million for the same period in 2021, primarily due to an expanded R&D team[33]. - Research and development costs for the current year amounted to RMB 6,745,000, significantly higher than RMB 3,472,000 in the previous year, reflecting an increase of 94.5%[126]. Strategic Initiatives - The company is focusing on expanding its market presence and enhancing its product offerings to drive future growth[14]. - New product development initiatives are underway, aimed at leveraging technology advancements to improve operational efficiency[14]. - The company plans to explore strategic partnerships and potential acquisitions to accelerate growth and market penetration[14]. - The company signed a strategic cooperation agreement with PwC and Sichuan Huakun Zhenyu Intelligent Technology Co., Ltd. to accelerate the application and promotion of RPA products[19]. - A preliminary memorandum of understanding was reached with the major shareholder of Jiangxi Shangtong Technology Development Co., Ltd. for a potential acquisition to enhance innovative solution capabilities[22]. - The company entered into a share purchase agreement to acquire all issued shares of Samton (Cayman) Holdings Limited for a maximum consideration of RMB 486 million, which will make the target company a wholly-owned subsidiary[169]. Financial Guidance and Outlook - Future guidance indicates a positive outlook with expectations of continued revenue growth and improved profitability in the upcoming quarters[14]. - The company plans to enhance its sales and marketing efforts, allocating 10% of the IPO proceeds for this purpose, amounting to HKD 79.1 million[70]. - The establishment of Hainan Xinyou aims to expand regional business and enhance market penetration in Southeast coastal areas[75]. Governance and Compliance - The company has adopted the corporate governance code and has complied with its provisions since the listing date until June 30, 2021, with the exception of deviation from code A.2.1 regarding the separation of roles between the Chairman and CEO[62]. - The audit committee, consisting of three members, has reviewed the interim financial results for the six months ended June 30, 2021, which have not been audited but were prepared in accordance with applicable accounting standards[64]. Employee and Management Information - Employee costs, including director remuneration, were approximately RMB 46.0 million for the six months ended June 30, 2021, with a total of 468 employees[52]. - The total compensation for key management personnel was RMB 1,256,000 for the six months ended June 30, 2021, compared to RMB 713,000 for the same period in 2020, representing an increase of approximately 76%[167].

Product Development and Launches - The company launched a financial institution RPA solution in 2018, followed by a series of product launches including a distributed trading platform in 2019 and a smart healthcare implementation plan in 2020[16]. - The company plans to enhance its RPA platform and medical big data solutions to increase market share in 2021[25]. - New product launches are anticipated to contribute an additional $C million in revenue, with a focus on innovative technology solutions[31]. - The company focused on upgrading its medical quality control and safety warning systems to enhance data processing efficiency and accuracy[49]. - The company plans to enhance market competitiveness by exploring and promoting innovative solutions, including RPA solutions and medical quality control platforms, while increasing investment in R&D and marketing[59]. Financial Performance - Total revenue for 2020 increased by 18.2% to RMB 176.1 million from RMB 149.0 million in 2019[23]. - Gross profit for 2020 was RMB 92.4 million, up from RMB 73.2 million in 2019, reflecting a significant growth[23]. - Adjusted net profit for 2020 reached RMB 50.2 million, compared to RMB 38.3 million in 2019, marking a 31.1% increase[23]. - The total assets as of December 31, 2020, amounted to RMB 258.5 million, an increase from RMB 245.1 million in 2019[23]. - The total liabilities as of December 31, 2020, were RMB 59.1 million, slightly up from RMB 58.2 million in 2019[23]. - The company reported a significant increase in revenue, achieving a total of $X million for the fiscal year, representing a Y% growth compared to the previous year[31]. - Revenue for 2020 rose by 18.2% to RMB 176.1 million from RMB 149.0 million in 2019, driven by an increase in medical big data solutions revenue from RMB 12.3 million to RMB 33.7 million and IT solutions for financial institutions from RMB 127.0 million to RMB 136.9 million[60]. - The number of financial institution clients increased from 74 in 2019 to 85 in 2020, contributing to a revenue growth of 7.8% in the financial IT solutions segment[61]. - The medical big data solutions revenue grew 2.74 times to RMB 33.7 million in 2020, with the solutions being promoted to 90 medical institutions, doubling the number from 2019[62]. - Profit before tax increased slightly to RMB 403 million in 2020 from RMB 382 million in 2019[73]. - Net profit slightly decreased by 3.3% to RMB 320 million in 2020 from RMB 331 million in 2019, with a net profit margin dropping from 22.2% to 18.2%[75]. Research and Development - The company will continue to invest in R&D and marketing for AI and big data analysis solutions in 2021[25]. - Ongoing research and development efforts are focused on advancing AI and machine learning capabilities, with an investment of $F million allocated for this purpose[31]. - R&D expenses decreased by 16.8% from RMB 143 million in 2019 to RMB 119 million in 2020, primarily due to a reduction in employee-related costs[69]. - 34.5% of the company's R&D personnel are familiar with the medical industry and possess expertise in medical quality control[50]. - As of December 31, 2020, all R&D personnel held at least a bachelor's degree, with approximately 5.5% holding a master's degree or higher[50]. Corporate Governance - The board of directors is committed to maintaining high standards of corporate governance to protect shareholder interests and enhance corporate value[91]. - The audit committee, consisting of three independent non-executive directors, was established to review financial information and oversee the financial reporting system, risk management, and internal control systems[110]. - The company has established a three-year initial term for both executive and independent non-executive directors starting from December 5, 2020[103][104]. - The company has adopted a board diversity policy to enhance board efficiency and maintain high levels of corporate governance, considering factors such as gender, skills, age, professional experience, knowledge, cultural background, and tenure when selecting board candidates[118]. - The company has established appropriate liability insurance for directors and senior management against legal actions arising from company activities[106]. Environmental, Social, and Governance (ESG) Initiatives - The company adheres to ESG principles, actively engaging with stakeholders to address their concerns and improve governance strategies[144]. - The company has implemented a waste management process, including the classification of office waste into recyclable, hazardous, and kitchen waste categories[150]. - The company emphasizes resource conservation and has developed a comprehensive energy management policy to enhance resource efficiency[151]. - The company is committed to reducing greenhouse gas emissions generated from operational activities, including energy use and vehicle emissions[150]. - Total greenhouse gas emissions for 2020 were 86.53 tons, with a per capita emission of 0.19 tons[159]. Employee Welfare and Safety - The company has implemented a free annual health check for employees with over one year of service, targeting specific health needs based on gender and marital status[175]. - In 2020, the company reported no workplace injuries or COVID-19 infections among employees[176]. - The company established a flexible working mechanism during the pandemic to ensure employee safety and well-being[176]. - A comprehensive employee health monitoring system was implemented, including daily health checks and a health reporting app[176]. - The company encourages employee feedback through established reporting and communication channels[179]. Financial Management and Risk Control - The company has adopted specific policies covering reimbursement management, cash management, budget management, and credit management to enhance financial management[87]. - The company implemented strict controls on accounts receivable to minimize credit risk and improve cash flow[87]. - The company has established a comprehensive anti-fraud management system to ensure compliance with relevant laws and regulations[190]. - The company actively participates in community investment and social responsibility initiatives, responding to community needs and expectations[191]. - The company has implemented internal management measures to reduce incidents of corruption and fraud, including background checks on potential hires[190].